IHF:NYE-iShares U.S. Healthcare Providers ETF (USD)

ETF | Health |

Last Closing

USD 57.03

Change

-0.19 (-0.33)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.31 (-0.20%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

-0.12 (-0.16%)

USD 3.01B
FXH First Trust Health Care AlphaD..

-0.50 (-0.45%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.47 (-0.52%)

USD 0.23B
IDNA iShares Genomics Immunology an..

+0.10 (+0.41%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.19 (-0.49%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-0.39 (-0.40%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.19%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.08 (-0.13%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.16 (+0.55%)

USD 0.01B

ETFs Containing IHF

LCR Leuthold Core ETF 4.21 % 0.00 %

+0.05 (+0.14%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.61% 48% F 51% F
Dividend Return 0.25% 38% F 4% F
Total Return 8.86% 48% F 44% F
Trailing 12 Months  
Capital Gain 14.88% 10% F 47% F
Dividend Return 0.47% 50% F 5% F
Total Return 15.35% 14% F 40% F
Trailing 5 Years  
Capital Gain 77.69% 100% F 80% B-
Dividend Return 4.22% 56% F 12% F
Total Return 81.91% 100% F 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 9.24% 90% A- 67% D+
Dividend Return 9.87% 81% B- 62% D
Total Return 0.63% 63% D 15% F
Risk Return Profile  
Volatility (Standard Deviation) 16.94% 57% F 59% D-
Risk Adjusted Return 58.26% 71% C- 76% C+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:

There is nothing we particularly dislike